Efficacy and safety of fluticasone propionate in therapy of children suffering from asthma: Part II. Safety aspects of therapy with fluticasone propionate in asthmatic children;Skuteczność i bezpieczeństwo stosowania propionianu flutikazonou w leczeniu astmy oskrzelowej u dzieci: Cześć II. Bezpieczeństwo stosowania propionianu flutikazonu w leczeniu astmy oskrzelowej u dzieci

Polski Merkuriusz Lekarski

Volumn 17, Issue SUPPL. 2, 2004, Pages 11-18

  Bartkowiak Emeryk, Małgorzta ^a   Brȩborowicz, Anna ^b   Emeryk, Andrzej ^a   Kulus, Marek ^c   Kurzawa, Ryszard ^a   Lis, Grzegorz ^d   Mazurek, Henryk ^a   Niedziela, Marek ^b  

^a Akademia Medyczna ^*  (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

^d JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Adrenal function; Asthma; Bone metabolism; Children; Fluticasone propionate; Growth and height

Indexed keywords

BUDESONIDE; FLUTICASONE PROPIONATE; GLUCOCORTICOID;

ADRENAL INSUFFICIENCY; ADRENAL SUPPRESSION; ASTHMA; BODY HEIGHT; BONE DENSITY; BONE METABOLISM; BONE MINERAL; CHILD; CHILDHOOD DISEASE; DISEASE CONTROL; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; FIRST PASS EFFECT; FRACTURE; GROWTH REGULATION; GROWTH RETARDATION; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; LIVER METABOLISM; LONG TERM CARE; OSTEOPOROSIS; REVIEW; RISK ASSESSMENT; SIDE EFFECT; STEROID THERAPY;

ADMINISTRATION, INHALATION; ADOLESCENT; AGE FACTORS; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; BONE DENSITY; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INFANT; INFANT, NEWBORN; MALE; OSTEOPOROSIS; PITUITARY-ADRENAL SYSTEM; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; TREATMENT OUTCOME;

EID: 8844244786     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Crowley S. Inhaled glucocorticoids and adrenal function: an update. Paediatr. Respir. Rev. 2003, 4, 2, 153-161.
2. Derom E i wsp.: Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma. Am. J. Respir. Crit. Care Med., 1999, 160, 1, 157-161.
3. Broide J. i wsp.: Low-dose adrenocorticotropin test reveals impaired adrenal function in patients taking inhaled corticosteroids. J. Clin. Endocrinol. Metab., 1995, 80, 4, 1243-1246.
4. Malo J.L. i wsp.: Skin bruising, adrenal function and markers of bone metabolism in asthmatics using inhaled beclomethasone and fluticasone. Eur. Respir. J., 1999, 13, 5, 993-8.
5. Rao R. i wsp.: Systemic effects of inhaled corticosteroids on growth and bone turnover in childhood asthma: a comparison of fluticasone with beclomethasone. Eur. Respir. J., 1999, 13, 1, 87-94.
6. Niitsuma T. i wsp.: Adrenal function as assessed by low-dose adrenocorticotropin hormone test before and after switching from inhaled beclomethasone dipropionate to inhaled fluticasone propionate. J. Asthma, 2003, 40, 5, 515-522.
7. Harrison T.W. i wsp.: Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects. Thorax, 2001, 56, 3, 186-191.
8. Harmanci E. i wsp.: Fluticasone propionate and budesonide do not influence bone metabolism in the long term treatment of asthma. Allergol. Immunopathol. (Madr). 2001, 29, 1, 22-27.
9. Barnes N.S., Hallet C., Harris T.A.: Clinical experience with fluticasone propionate in asthma: a metaanalysis of efficacy and systemic activity compared with budesonide and beclomethasone dipropionate at half the milligram dose or less. Respir. Med., 1998, 92, 95-105.
10. Ringdal N. i wsp.: Comparable effects of inhaled fluticasone propionate and budesonide on the HPA-axis in adult asthmatic patients. Respir. Med., 2000, 94, 5, 482-489.
11. Nielsen L.P., Dahl R.: Therapeutic ratio of inhaled corticosteroids in adult asthma. A dose-range comparison between fluticasone propionate and budesonide, measuring their effect on bronchial hyperresponsiveness and adrenal cortex function. Am. J. Respir. Crit. Care Med., 2000, 162, 6, 2053-2057.
12. Kannisto S. i wsp.: Efficacy and safety of inhaled steroid and cromone treatment in school-age children: a randomized pragmatic pilot study. Pediatr. Allergy Immunol., 2002, 13, 1, 24-30.
13. Kannisto S. i wsp.: Adrenal suppression, evaluated by a low dose adrenocorticotropin test, and growth in asthmatic children treated with inhaled steroids. J. Clin. Endocrinol. Metab., 2000, 85, 2, 652-657.
14. Lipworth B.J.: Systemic adverse effects of inhaled corticosteroid therapy: a systemic review and metaanalysis. Arch. Intern. Med., 1999, 159, 941-955.
15. Donnelly R. wsp.: Effects of budesonide and fluticasone on 24-hour plasma cortisol. A dose-response study. Am. J. Respir. Crit. Care Med., 1997, 156, 6, 1746-17451.
16. Martin R.J. i wsp.: Systemic effect comparisons of six inhaled corticosteroid preparations. Am. J. Respir. Crit. Care Med., 2002, 165, 10, 1377-1383.
17. Karlberg J. i wsp.: Analysis of linear growth using a mathematical model. 1. From birth to three years. Acta Paediatr. Scand., 1987, 76, 3, 478-488.
18. Karlberg J., Gelander L., Albertsson-Wikland K.: Distinctions between short- and long-term human growth studies. Acta Pediatr., 1993, 82, 631-634.
19. Low L., Yeung C.Y.: On the dynamics of the growth process. Acta Pediatr., 1994, 83, 777-778.
20. Sorkness C.A.: Establishing a therapeutic index for inhaled corticosteroids: part II. J. Allergy Clin. Immunol., 1998, 102, 4 Pt 2, S52-S64.
21. Allen D.B.: Safety of inhaled corticosteroids in children. Pediatr. Pulmonol., 2002, 33, 3, 208-220.
22. Allen D.B. i wsp.: Inhaled corticosteroids: Past lessons and future issues. J. Allergy Clin. Immunol., 2003, 112, S1-S40.
23. Efthimiou J., Barnes P.J.: Effect of inhaled corticosteroids on bones and growth. Eur. Respir. J. 1998, 11, 5, 1167-1177.
24. Luo Z.C., Low L.C., Karlberg J.A.: A comparison of target height estimated and final height attained between Swedish and Hong Kong Chinese children. Acta Paediatr., 1999, 88, 3, 248-252.
25. Balfour Lynn L.: Growth and childhood asthma. Arch. Dis. Child, 1987, 61, 11, 1049-1055.
26. Russell G.: Asthma and growth. Arch. Dis. Child, 1993, 69, 6, 695-698.
27. Oberger E., Engstrom I., Karlberg J.: Long-term treatment with glucocorticoids/ACTH in asthmatic children. III. Effects on growth and adult height. Acta Pediatr. Scand., 1990, 79, 1, 77-83.
28. Shohat M. i wsp.: Childhood asthma and growth outcome. Arch. Dis. Child, 1987, 62, 1, 63-65.
29. Spock A.: Growth patterns in 200 children with childhood asthma. Ann. Allergy, 1965, 23, 12, 608-615.
30. Hauspie R., Susanne C., Alexander F.: Maturational delay and szybkośćral growth retardation in asthmatic boys. J. Allergy Clin. Immunol., 1977, 59, 3, 200-206.
31. Ninan T., Russell G.: Asthma, inhaled corticosteroid treatment, and growth. Arch. Dis. Child, 1992, 67, 6, 703-705.
32. Woithers O., Pedersen S.: Short term linear growth in asthmatic children during treatment with prednisolone. BMJ 1990, 301, 6744, 145-148.
33. Silverstein M.D. i wsp.: Attained adult height after childhood asthma: effect of glucocorticoid therapy. J. Allergy Clin. Immunol., 1997, 99, 4, 466-474.
34. Van Bever H.P. i wsp.: Does treatment of asthmatic children with inhaled corticosteroids affect their adult height? Pediatr. Pulmonol., 1999, 27, 6, 369-375.
35. Price J.F. i wsp.: Growth during one year of treatment with fluticasone propionate or sodium cromoglycate in children with asthma. Pediatr. Pulmonol., 1997, 24, 3, 178-186.
36. Allen D.B. i wsp.: Growth in asthmatic children treated with fluticasone propionate. J. Pediatr., 1998, 132, 3Pt1, 472-477.
37. MacKenzie C.A., Wales J.K.H.: Clinical experience with inhaled fluticasone propionate - childhood growth. Am. J. Respir. Crit Care Med. 1994, 150: 351.
38. Konig O. i wsp.: A 1-year comparison of the effects of inhaled fluticasone propionate and placebo on growth in prepubescent children with asthma. Eur. Respir. J., 1996, 9, suppl.23, S294.
39. Whitaker K. i wsp.: Effect of fluticasone on growth in children with asthma. Lancet, 1996, 348, 9019, 63-64.
40. Ferguson A.C. i wsp.: Efficacy and safety of high-dose inhaled steroids in children with asthma: a comparison of fluticasone propionate with budesonide. J. Pediatr., 1999, 134, 4, 422-427.
41. de Benedictis F.M. i wsp.: Effects of 2 inhaled corticosteroids on growth: results of a randomized controlled trial. Arch. Pediatr. Adolesc. Med., 2001, 155, 11, 1248-1254.
42. Turktas I. i wsp.: Safety of inhaled corticosteroid therapy in young children. Ann. Allergy Asthma Immunol., 2001, 86, 6, 649-654.
43. Visser M.J. i wsp.: One-year with different dosing schedules of fluticasone propionate in childhood asthma. Effects on hyperresponsiveness, lung function, and height. Am. J. Respir. Crit. Care Med., 2001, 164, 11, 2073-2077.
44. Todd G. i wsp.: Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate. Lancet, 1996, 348, 9019, 27-29.
45. Wong J.Y. i wsp.: Growth and adrenal suppression in asthmatic children on moderate to high doses of fluticasone propionate. J. Paediatr. Child Health, 2002, 38, 1, 59-62.
46. Sharek P.J., Bergman D.A.: The effect of inhaled steroids on the linear growth of children with asthma: a meta-analysis. Pediatrics, 2000, 106, 1, e8.
47. Bisgaard H. iwsp.: Twelve-month safety and efficacy of inhaled fluticasone propionate in children aged 1 to 3 years with recurrent wheezing. Pediatrics, 2004, 113, 2, E87-E94.
48. Teper A.M. i wsp.: Effects of inhaled fluticasone propionate in children less than 2 years old with recurrent wheezing. Pediatr. Pulmonol., 2004, 37, 2, 111-115.
49. MacKenzie C.A., Wales J.K.H.: Knemometry and its practical application. Eur. Respir. Rev., 1993, 3: 321-325.
50. Wolthers O.D., Pedersen S.: Short-term growth during treatment with inhaled fluticasone propionate and beclomethasone dipropionate. Arch. Dis. Child, 1993, 68, 5, 673-676.
51. Barnes N.: Relative safety and efficacy of inhaled corticosteroids. J. Allergy Clin. Immunol., 1998, 101,4 Pt 2, S 460-464.
52. Agertoft L., Pedersen S.: Short term knemometry and urine cortisol excretion in children treated with fluticasone propionate and budesonide: a dose response study. Eur. Respir. J., 1997, 10, 7, 1507-1512.
53. Visser M.J. i wsp.: Short-term growth in asthmatic children using fluticasone propionate. Chest, 1998, 113, 3, 584-586.
54. Anhoj J., Bisgaard A.M., Bisgaard H.: Systemic activity of inhaled steroids in 1- to 3-year-old children with asthma. Pediatrics, 2002, 109, 3, E40.
55. Gordon C.L. i wsp.: The contributions of growth and puberty to peak bone mass. Growth Dev. Aging., 1991, 55, 4, 257-262.
56. Clark C.J., Cochrane L.M.: Assessment of work performance in asthma for determination of cardiorespiratory fitness and training capacity. Thorax, 1988, 43, 10, 745-749.
57. Koning P. i wsp.: Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate. J. Pediatr., 1993, 122, 2, 219-226.
58. Weistein R.S. i wsp.: Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblast and osteocytes by glucocorticoids. Potential mechanism of their deleterious effects of bone. J. Clin. Invest., 1998, 102, 2, 274-282.
59. Kaji H. i wsp.: Dexamethasone stimulates osteoclast-like cell formation by directly acting on hemopoietic blast cells and enhances osteoclast- like cell formation stimulated by parathyroid hormone and prostaglandin E2. J. Bone Miner. Res., 1997, 12, 5, 734-741.
60. Misra M. i wsp.: Serum osteoprotegerin in adolescent girls with anorexia nervosa. J. Clin. Endocrinol. Metab., 2003, 88, 8, 3816-3822.
61. Yaghoobian J., Drueke T.B.: Regulation of the transcription of parathyroid-hormone/ parathyroid-hormone-related peptide receptor mRNA by dexamethasone in ROS 17/2.8 osteosarcoma cells. Nephrol. Dial. Transplant., 1998, 13, 3, 580-586.
62. Adler R.A., Rosen C.J.: Glucocorticoids and osteoporosis. Endocrinol. Metab. Clin. North Am., 1994, 23, 3, 641-653.
63. Światowa strategia rozpoznawania, leczenia i prewencji astmy. Raport NHLBI/WHO. Publikacja Nr 02-3569. Med. Prakt. 2002, wydanie specjalne, 6, 1-181.
64. Barnes P., Pedersen S., Busse W.W.: Efficacy and safety of inhaled corticosteroids: new developments. Am. J. Respir. Crit. Care Med., 1998, 157, 3 Pt 2, S1-S53.
65. Reilly S.M. i wsp.: Bone density in asthmatic children treated with inhaled corticosteroids. Arch. Dis. Child, 2001, 84, 2, 183-184.
66. Gregson R.K. i wsp.: Effect of inhaled corticosteroids on bone mineral density in childhood asthma: comparison of fluticasone propionate with beclomethasone dipropionate. Osteoporosis Int., 1998, 8, 5, 418-422.
67. Griffiths A.L. i wsp.: Effect of high-dose fluticasone propionate on bone density and metabolism in children with asthma. Pediatr. Pulmonol., 2004, 37, 2, 116-121.
68. Hoekx J.C.M. i wsp.: Fluticasone propionate compared with budesonide: double-blind trial in asthmatic children using powder devices at a dosage of 400 μg/day-1. Eur. Respir. J., 1996, 9, 11, 2263-2272.
69. Kannisto S. i wsp.: Biochemical markers of bone metabolism in relation to adrenocortical and growth suppression during the initial phase of inhaled steroid therapy. Pediatr. Res., 2002, 52, 2, 258-262.
70. Karakoc F. i wsp.: A comparison of the efficacy and safety of a half dose of fluticasone propionate with beclomethasone dipropionate and budesonide in childhood asthma. J. Asthma, 2001, 38, 3, 229-237.
71. Roux C. i wsp.: Long-term safety of fluticasone propionate and nedocromil sodium on bone in children with asthma. Pediatrics, 2003, 111, 6 Pt 1, E706-E713.
72. Ducharme F.M. i wsp.: Safety profile of frequent short courses of oral glucocorticoids in acute pediatric asthma: impact on bone metabolism, bone density, and adrenal function. Pediatrics, 2003, 111, 2, 376-383.
73. Agertoft L., Pedersen S.: Bone mineral density in children with asthma receiving long-term treatment with inhaled budesonide. Am. J. Respir. Crit. Care Med., 1998, 157, 1, 178-183.
74. Martinati L.C. i wsp.: Effect on cortical and trabecular bone mass of different antyinflammatory treatments in preadolescent children with chronic asthma. Am. J. Respir. Crit. Care Med., 1996, 153, 1, 323-326.
75. Luengo M. i wsp.: Vertebral fracture in steroid dependent asthma and involutional osteoporosis: a comparative study. Thorax, 1991, 46,11, 803-806.